PrEP Not Reaching Most Who Could Potentially Benefit

A new CDC study suggests that only a small percentage of Americans who could potentially benefit from pre-exposure prophylaxis (PrEP), a daily pill for HIV prevention, have been prescribed it. In the first detailed analysis by race and by risk group, CDC researchers found while two-thirds of those who could potentially benefit from PrEP are African American or Latino, these groups account for the smallest percentage of prescriptions to date.

Key Findings

In 2015, there were approximately 1.1 million Americans who could potentially benefit from PrEP according to CDC guidelines, including:

 

500,000 African Americans

 

300,000 Latinos

 

300,000 whites

However, during a similar time period (September 2015 – August 2016), prescriptions filled at retail pharmacies or mail order services included as few as:

 

7,000 for African Americans

 

7,600 for Latinos

 

42,000 for whites

[chart]

"One of our most powerful tools for HIV prevention remains largely on pharmacy shelves."

– Jonathan Mermin, MD, MPH, Director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

 

"Closing gaps is an important step for PrEP."

– Eugene McCray, MD, Director of CDC's Division of HIV/AIDS Prevention

 

"We now have a powerful picture of where PrEP's potential impact could be greatest."

– Dawn K. Smith, MD, MPH, MS, Epidemiologist and Medical Officer in CDC's Division of HIV/AIDS Prevention

Connect with us